Ally Bridge Group NY LLC grew its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 145.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,229,292 shares of the company's stock after buying an additional 729,292 shares during the period. Eliem Therapeutics accounts for 3.3% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 13th largest position. Ally Bridge Group NY LLC owned about 4.13% of Eliem Therapeutics worth $6,257,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. Rhumbline Advisers bought a new stake in Eliem Therapeutics during the second quarter valued at $59,000. SG Americas Securities LLC purchased a new stake in Eliem Therapeutics in the third quarter valued at approximately $60,000. Valence8 US LP purchased a new stake in Eliem Therapeutics in the third quarter valued at approximately $61,000. Dimensional Fund Advisors LP purchased a new position in Eliem Therapeutics in the 2nd quarter worth approximately $89,000. Finally, Chicago Partners Investment Group LLC purchased a new stake in shares of Eliem Therapeutics during the 3rd quarter valued at $81,000. 69.76% of the stock is owned by institutional investors.
Eliem Therapeutics Stock Up 5.9 %
NASDAQ:ELYM traded up $0.18 during midday trading on Thursday, hitting $3.22. The company had a trading volume of 135,419 shares, compared to its average volume of 486,688. The stock's fifty day moving average price is $4.59 and its 200-day moving average price is $6.46. Eliem Therapeutics, Inc. has a 52-week low of $2.35 and a 52-week high of $11.55. The company has a market capitalization of $95.80 million, a PE ratio of -6.08 and a beta of -0.39.
Eliem Therapeutics Profile
(
Free Report)
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Recommended Stories
Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
